Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab
Abstract Duchenne muscular dystrophy (DMD) is a progressive, neuromuscular disorder caused by mutations in the DMD gene that results in a lack of functional dystrophin protein. Herein, we report the use of quantitative magnetic resonance imaging (MRI) measures as biomarkers in the context of a multicenter phase 2, randomized, placebo-controlled clinical trial evaluating the myostatin inhibitor domagrozumab in ambulatory boys with DMD (n = 120 aged 6 to < 16 years). MRI scans of the thigh to measure muscle volume, muscle volume index (MVI), fat fraction, and T2 relaxation time were obtained at baseline and at weeks 17, 33, 49, and 97 as per protocol. These quantitative MRI measurements appeared to be sensitive and objective biomarkers for evaluating disease progression, with significant changes observed in muscle volume, MVI, and T2 mapping measures over time. To further explore the utility of quantitative MRI measures as biomarkers to inform longer term functional changes in this cohort, a regression analysis was performed and demonstrated that muscle volume, MVI, T2 mapping measures, and fat fraction assessment were significantly correlated with longer term changes in four-stair climb times and North Star Ambulatory Assessment functional scores. Finally, less favorable baseline measures of MVI, fat fraction of the muscle bundle, and fat fraction of lean muscle were significant risk factors for loss of ambulation over a 2-year monitoring period. These analyses suggest that MRI can be a valuable tool for use in clinical trials and may help inform future functional changes in DMD. Trial registration: ClinicalTrials.gov identifier, NCT02310763; registered December 2014..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:269 |
|---|---|
| Enthalten in: |
Journal of neurology - 269(2022), 8 vom: 08. Apr., Seite 4421-4435 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sherlock, Sarah P. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s00415-022-11084-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR047625732 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR047625732 | ||
| 003 | DE-627 | ||
| 005 | 20230519183231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220719s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00415-022-11084-0 |2 doi | |
| 035 | |a (DE-627)SPR047625732 | ||
| 035 | |a (SPR)s00415-022-11084-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sherlock, Sarah P. |e verfasserin |0 (orcid)0000-0001-5351-3828 |4 aut | |
| 245 | 1 | 0 | |a Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Abstract Duchenne muscular dystrophy (DMD) is a progressive, neuromuscular disorder caused by mutations in the DMD gene that results in a lack of functional dystrophin protein. Herein, we report the use of quantitative magnetic resonance imaging (MRI) measures as biomarkers in the context of a multicenter phase 2, randomized, placebo-controlled clinical trial evaluating the myostatin inhibitor domagrozumab in ambulatory boys with DMD (n = 120 aged 6 to < 16 years). MRI scans of the thigh to measure muscle volume, muscle volume index (MVI), fat fraction, and T2 relaxation time were obtained at baseline and at weeks 17, 33, 49, and 97 as per protocol. These quantitative MRI measurements appeared to be sensitive and objective biomarkers for evaluating disease progression, with significant changes observed in muscle volume, MVI, and T2 mapping measures over time. To further explore the utility of quantitative MRI measures as biomarkers to inform longer term functional changes in this cohort, a regression analysis was performed and demonstrated that muscle volume, MVI, T2 mapping measures, and fat fraction assessment were significantly correlated with longer term changes in four-stair climb times and North Star Ambulatory Assessment functional scores. Finally, less favorable baseline measures of MVI, fat fraction of the muscle bundle, and fat fraction of lean muscle were significant risk factors for loss of ambulation over a 2-year monitoring period. These analyses suggest that MRI can be a valuable tool for use in clinical trials and may help inform future functional changes in DMD. Trial registration: ClinicalTrials.gov identifier, NCT02310763; registered December 2014. | ||
| 650 | 4 | |a Duchenne muscular dystrophy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Domagrozumab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a MRI |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biomarkers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Imaging |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neuromuscular disease |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Palmer, Jeffrey |4 aut | |
| 700 | 1 | |a Wagner, Kathryn R. |4 aut | |
| 700 | 1 | |a Abdel-Hamid, Hoda Z. |4 aut | |
| 700 | 1 | |a Bertini, Enrico |4 aut | |
| 700 | 1 | |a Tian, Cuixia |4 aut | |
| 700 | 1 | |a Mah, Jean K. |4 aut | |
| 700 | 1 | |a Kostera-Pruszczyk, Anna |4 aut | |
| 700 | 1 | |a Muntoni, Francesco |4 aut | |
| 700 | 1 | |a Guglieri, Michela |4 aut | |
| 700 | 1 | |a Brandsema, John F. |4 aut | |
| 700 | 1 | |a Mercuri, Eugenio |4 aut | |
| 700 | 1 | |a Butterfield, Russell J. |4 aut | |
| 700 | 1 | |a McDonald, Craig M. |4 aut | |
| 700 | 1 | |a Charnas, Lawrence |4 aut | |
| 700 | 1 | |a Marraffino, Shannon |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology |d [Darmstadt] : Steinkopff, 1891 |g 269(2022), 8 vom: 08. Apr., Seite 4421-4435 |w (DE-627)SPR005310695 |w (DE-600)1421299-7 |x 1432-1459 |7 nnns |
| 773 | 1 | 8 | |g volume:269 |g year:2022 |g number:8 |g day:08 |g month:04 |g pages:4421-4435 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00415-022-11084-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 269 |j 2022 |e 8 |b 08 |c 04 |h 4421-4435 | ||